Anna Schmitt is an expert in Hematology at Institut Bergonié (France). Anna Schmitt has authored 88 publications, the most recent in 2025, and is an investigator in 7 clinical trials. SLR score: 223 (community average: 125). How the SLR is computed.

LeadR Profile

Anna Schmitt Institut Bergonié France
223 ScienceLeadR Reputation 223
Network Map

Hematology

Subspecialties: Oncology - Medical Imaging - Immunology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Expert Rankings

Top experts on the MeSH terms this expert works on

Organizations

Career arc: 2012 - 2025

Source: PubMed

Institut Bergonié

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 88

Citations

Citations: 3 089 1st author: 2 Last author: 2 Unique author: 0


Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
High-risk genomic consensus validation for patients with newly diagnosed multiple myeloma using next-generation sequencing.
PMID 40991836 — high-throughput nucleotide sequencing, multiple myeloma, diagnosis, cytogenetics
Blood20250
Automatic Segmentation of Primary Central Nervous System Lymphoma at Clinical Routine Postcontrast T1-weighted MRI.
PMID 40970793 — lymphoma, central nervous system, deep learning, nervous system, learning, wounds and injuries
Radiol Imaging Cancer20250
Primary central nervous system lymphoma of the spinal cord: A LOC network cohort study.
PMID 39706697 — spinal cord, lymphoma, brain, cohort studies, biopsy, central nervous system, diagnosis, nervous system, neurology, spine
Rev Neurol (Paris)20240
Correction: Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients.
PMID 39427203 — research design, lymphoma, central nervous system, lenalidomide, nervous system
J Hematol Oncol Top journal20240
Long-term analysis of the RiBVD phase II trial reveals the unfavorable impact of mutations and hypoalbuminemia in older adults with mantle cell lymphoma; for the LYSA group.
PMID 38031755 — hematology, cells, mutation, hypoalbuminemia, lymphoma, mantle-cell, disease-free survival, multivariate analysis, progression-free survival
Haematologica20242

Clinical Studies 7

Sources: ClinicalTrials, EU CTIS

Synthesis

By phase:

Phase 2 3
N/A 1
Phase 1/Phase 2 1
Phase 2/Phase 3 1
Phase 3 1

By status:

Completed 5
Active not recruiting 1
Recruiting 1

By type:

Interventional 6
Observational 1

By Monocentric/Multicentric:

monocentric 2
multicentric2to4 0
multicentric5to9 1
multicentricup10 4

Main Topics

LeadR Networks

Main global connection map